Executive Summary: Key Legal and Evidentiary Issues

• Effect of British Columbia’s Limitation Act on Amaranthus’s underlying margin debt and whether expiry of the limitation period extinguished or merely barred remedies on that debt.
• Operation of the “principal debtor” clause and account-statement clause in Mr. Vita’s personal guarantee, and how they extended his liability beyond that of a typical guarantor.
• Sufficiency of evidence proving the US$3 million loan advance and the proper evidentiary basis for contractual interest and surcharges on the margin account.
• Scope of any duty on Canaccord to mitigate its loss by selling pledged Columbia Care shares and the impact of guarantee wording that insulated Canaccord’s choices about security.
• Viability of an illegality / ex turpi causa defence based on alleged circumvention of U.S. securities and cannabis-related laws through the Amaranthus structure.
• Appropriateness of resolving all issues, including illegality and complex limitation questions, by way of summary trial rather than full conventional trial.

Background and parties
Canaccord Genuity Corp. is an Ontario-incorporated financial services firm providing investment banking and brokerage services across Canada. Nicholas Vita, resident in Greenwich, Connecticut, served from 2012 to 2024 as Chief Executive Officer of Columbia Care LLC and Columbia Care Inc., cannabis companies whose publicly traded shares later formed the collateral at the heart of this dispute. Canaccord acted as underwriter and advisor when it took Columbia Care public on a Canadian stock exchange in April 2019, cementing its relationship with both Mr. Vita and Columbia Care’s executive chair, Michael Abbott. When a large, share-secured margin lending arrangement later soured, Canaccord sued Mr. Vita in the Supreme Court of British Columbia to enforce a personal guarantee, seeking recovery of millions of dollars said to be outstanding in a margin account formally held by an Isle of Man company, Amaranthus. Mr. Justice Coval heard the case by summary trial.

Creation of the Amaranthus margin account
The commercial structure reflected the regulatory reality that Canaccord could not open a margin account for Mr. Vita personally under U.S. law. Because he was a U.S. citizen and Canaccord was not a registered U.S. broker-dealer, and because cannabis-related securities could not be used as collateral in the United States, Canaccord instead opened a margin facility in June 2019 for Amaranthus, an Isle of Man company beneficially owned through Mr. Abbott’s family trust. Two authorized signatories of Amaranthus’s sole director signed an Account Information Form, which incorporated Canaccord’s Client Account Agreement. Together, these documents made up the Account Agreement and identified Amaranthus as the account holder, with Canaccord empowered to decide borrowing limits and cancel the margin facility. Amaranthus deposited 10,630,500 Columbia Care (“CC”) shares as collateral, then worth about $6.50 per share. Against this security Canaccord advanced US$8.3 million on June 10, 2019, and a further US$3 million on July 5, 2019, into the margin account. The undisputed evidence showed that Amaranthus’s authorized representatives directed that the first advance be wired to a Connecticut law firm representing Mr. Vita and the second to Mr. Abbott. While this confirmed that loan proceeds were intended to benefit insiders, the court emphasized that all formal instructions came from Amaranthus and that Mr. Vita was never a director, signatory, or authorized representative of that company, nor entitled to instruct Canaccord on the account.

Mr. Vita’s personal guarantee and collateral arrangements
By late 2019, Columbia Care’s share price had declined to roughly $3.40. Mr. Vita then asked that Amaranthus be permitted to borrow an additional US$2 million in the margin account. Canaccord agreed, subject to two conditions: Amaranthus would pledge an additional 17 million CC shares, and Mr. Vita would personally guarantee Amaranthus’s indebtedness. On December 31, 2019, Mr. Vita signed the personal guarantee (the Guarantee). In discovery he accepted that he had the opportunity to read it, that he agreed to its terms, and that he understood it allowed Canaccord to pursue him directly for Amaranthus’s debt. The Guarantee was drafted broadly. It unconditionally guaranteed “all present and future debts and liabilities” of Amaranthus arising on default under the Account. It also contained a principal debtor clause in section 5: if, for any reason other than termination according to its terms, the guarantor was released from the Guarantee or ceased to be liable for the guaranteed obligations, he would nonetheless be liable to Canaccord as principal debtor in respect of those obligations. A further protective clause was section 8, which provided that accounts “as settled or stated” between Canaccord and Amaranthus would be conclusive as to amounts owing and binding on the guarantor. In parallel, on January 3, 2020, Mr. Abbott, as director of Amaranthus, signed an undertaking requiring Amaranthus to deposit the extra 17 million CC shares and to maintain a specified margin ratio between the market value of the shares and any outstanding loans. On January 6, 2020, the additional CC shares were in fact deposited, and on January 7 Canaccord advanced the extra US$2 million into the account. By the end of that month, the account held CC shares worth about CA$127 million securing just under US$14 million in debt.

Share price decline, partial repayments, and default
The market did not cooperate. Columbia Care’s share price continued to fall during 2020, putting the account out of compliance with the required margin ratio in the Amaranthus undertaking. Amaranthus responded by selling 850,000 CC shares in December 2020, applying more than US$3.5 million to reduce the debt. Further injections followed: in December 2021 Mr. Abbott paid US$1 million into the account, and in July 2022 Amaranthus paid another US$800,000. By mid-2022, the account still held CC shares worth approximately CA$30 million against a remaining loan balance of about US$6.7 million. For much of 2022 and 2023, Canaccord did not sell further CC shares. The evidence showed that a proposed acquisition of Columbia Care by an arm’s-length buyer was in play, and both Mr. Vita and Mr. Abbott cautioned that forced sales might depress the share price and jeopardize the deal, whereas a successful acquisition might improve the shares’ value and strengthen collateral coverage. That transaction ultimately collapsed in July 2023. Canaccord then resumed selling CC shares in November 2023 to further reduce the debt. Separately, between March and July 2024, Mr. Vita himself paid US$275,000 toward the margin debt. He testified that he made these payments because he was a guarantor on the account. After July 2024, neither Amaranthus nor Mr. Vita made further payments. On October 18, 2024, Canaccord cancelled the margin facility under section 3.5 of the Account Agreement and declared the outstanding indebtedness immediately due and payable. On the same day it issued a demand letter to Mr. Vita under the Guarantee, asserting that the total outstanding debt was US$6,933,951 and demanding payment by October 31, 2024.

The litigation and defences raised
Canaccord commenced proceedings in February 2025 by filing a Notice of Civil Claim in the Supreme Court of British Columbia, seeking to enforce the Guarantee. Mr. Vita filed his Response in May 2025, and the parties engaged in discovery and document production through late 2025. Canaccord moved for a summary trial, arguing that there were no genuine factual disputes requiring a full trial: Mr. Vita admitted signing the Guarantee and understanding its purpose, the Guarantee plainly covered Amaranthus’s indebtedness, and Canaccord’s Chief Risk Officer, Adrian Pelosi, swore that the account statements correctly showed a total indebtedness of US$7,391,516.82 as of July 31, 2025. Mr. Vita opposed, but largely on the basis of one of his substantive defences—illegality—rather than on procedural grounds. On the merits he advanced four main lines of defence. First, he argued that the underlying debt to Amaranthus was extinguished because any claim against Amaranthus itself was statute-barred under the Limitation Act, given his contention that the account had been in default since September 1, 2022 and that the two-year limitation period had expired by the end of August 2024. Second, he said Canaccord had not proven part of its claim: he professed uncertainty whether he had received the US$3 million July 2019 advance and argued that Canaccord’s initial affidavit materials did not contain evidence that Amaranthus had properly authorized that advance, nor did they adequately prove the applicable contractual interest rates and surcharges. Third, he claimed Canaccord had failed to mitigate its loss by prudently realizing on the CC share collateral. On his theory, if Canaccord had liquidated the shares at various points—particularly around September 2022 and July 2023—it could have paid off the entire loan, and its failure to do so was driven by its ongoing relationship with Columbia Care rather than by sound risk management. Fourth, he relied on an illegality or ex turpi causa defence, contending that the entire arrangement was structured as a sham to circumvent U.S. securities and cannabis-related laws: in substance, he said, he was the true borrower, his beneficially owned CC shares were the real collateral, and Amaranthus’s role as account holder was a device to conceal this and allow Canaccord to operate as an unregistered U.S. broker-dealer engaging with cannabis-related securities.

Limitation arguments and the effect of guarantee wording
On the limitation issue, the court began by distinguishing between extinguishing a debt and merely barring the remedy of a lawsuit. Under British Columbia’s former Limitation Act, section 9(1) explicitly provided that upon expiry of a limitation period the right and title of the claimant were “extinguished.” Earlier authority under that statute had treated the debt itself as wiped out once the limitation period ran, which could in turn extinguish a guarantor’s liability. The current Limitation Act, however, contains no such extinguishment clause. Instead, section 6(1) states that a court proceeding in respect of a claim must not be commenced more than two years after the claim is discovered. Drawing on analogous Ontario decisions and the legislative history, the judge held that under the current regime expiry of a limitation period ordinarily bars the remedy (the court proceeding) but does not extinguish the underlying obligation. On that foundation, even if Canaccord could no longer sue Amaranthus directly, the debt remained a valid legal obligation capable of supporting a separate claim against the guarantor. The wording of the Guarantee then became decisive. In section 5, the principal debtor clause provided that if, for any reason other than proper termination of the Guarantee, the guarantor was released or ceased to be liable for the guaranteed obligations, he would be liable as principal debtor for those obligations. The judge interpreted this as meaning that even if Amaranthus’s liability became unenforceable due to a limitation expiry, Mr. Vita’s promise to stand in its shoes as principal debtor remained effective. The court therefore rejected the argument that any limitation bar against Amaranthus automatically extinguished the guarantee. Mr. Vita also relied on section 27 of the Limitation Act, the non-judicial remedy clause, to argue that once a limitation ran against Amaranthus, Canaccord could not exercise any related remedy against him. The judge disagreed. That provision, he held, is aimed at self-help remedies (such as distraint for rent or extra-judicial seizure of collateral) that can be exercised without legal proceedings, and prevents a creditor from using those remedies once litigation is time-barred. It does not operate to nullify a separate cause of action on a guarantee. Having found that neither the statute nor the Guarantee language assisted Mr. Vita, the court concluded that his limitation defence failed without needing to decide precisely when the limitation period against Amaranthus began to run.

Evidence on the advances and interest calculations
The court next addressed the evidentiary objections. On the US$3 million July 2019 advance, Mr. Vita’s position was that Canaccord’s main affidavit materials did not include direct documentary proof that Amaranthus had authorized that loan. After hearing that submission, Canaccord filed reply evidence from Mr. Pelosi attaching a July 4, 2019 Amaranthus authorization letter, signed by authorized signatories of its director, authorizing the US$3 million advance. Although this reply came after the usual procedural deadline, the judge admitted it. He noted that Mr. Vita had himself put the account statements into evidence and that the authorization letter had already been disclosed in document production. There was no meaningful prejudice from its late formal tender. Combined with section 8 of the Guarantee, which treated settled account statements as conclusive and binding on the guarantor, the court found that Canaccord had adequately proven the US$3 million loan as part of the indebtedness. The treatment of interest evidence was more cautious. While the account statements showed running interest amounts, they did not transparently set out the applicable rates or explain periodic surcharges. Mr. Vita had challenged interest calculations in his Response, yet Canaccord only provided a detailed breakdown in a late reply affidavit from Mr. Pelosi explaining specific rates and identifying a 3 percent surcharge applied on several occasions. The judge held that this late explanation caused prejudice: because it came shortly before the resumed hearing, Mr. Vita had no fair opportunity to verify or contest the methodology. Canaccord, he said, should have included that information in its main materials once interest was clearly in issue. Accordingly, the court declined to rely on the late interest breakdown in fixing the precise amount owing. Instead, it ordered that if the parties could not agree on interest, the matter would be referred to the Registrar to determine and certify the correct contractual interest amount.

Mitigation, collateral realization, and risk allocation in the guarantee
On the alleged failure to mitigate, Mr. Vita pointed to periods when the value of the pledged CC shares substantially exceeded the outstanding debt, notably around September 2022 and when the proposed takeover collapsed in July 2023. He contended that a prudent lender, unconstrained by conflicts of interest, would have sold sufficient shares to extinguish the loan and that Canaccord’s hesitation, driven by its relationship with Columbia Care and hope for a higher post-acquisition share price, should prevent it recovering “avoidable” losses. The court held that this argument was foreclosed by the Guarantee’s text. Section 3.0 provided that Canaccord was not required to demand payment from or proceed against Amaranthus or any other person, or to enforce any security, before calling on the guarantor. Section 4.5(c) further stated that the guarantor’s liability would not be reduced, limited, or affected by “any acts done, omitted, suffered or permitted” by Canaccord in connection with Amaranthus or any security held for the guaranteed obligations. Taken together, these clauses allocated to Mr. Vita the risk of how and when Canaccord dealt with its security. Even if, as a matter of general law, a creditor can be criticized for failing to act prudently in realizing collateral, a guarantor who has agreed that the creditor’s handling of that collateral will not diminish his liability cannot later rely on those same acts or omissions as a defence. The judge therefore did not have to decide whether Canaccord’s choices met an objective “prudent lender” test, because the contract itself made those choices irrelevant to the guarantor’s liability.

Illegality and ex turpi causa defence
The most far-reaching defence was illegality. Mr. Vita argued that Canaccord and its affiliates could not, under U.S. law, operate a margin account for him personally using cannabis-related shares as collateral, and that the Amaranthus structure was a contrivance designed to circumvent those rules. He relied on an expert opinion from a former senior SEC prosecutor, who opined that the arrangement appeared to breach U.S. broker-dealer registration provisions, anti-fraud rules, and statutes such as the Controlled Substances Act, Money Laundering Control Act, and Bank Secrecy Act. Based on this, he said, the court should refuse to enforce the Guarantee under the ex turpi causa doctrine, which prevents plaintiffs from recovering for losses tied to their own unlawful conduct or for contracts formed for an illegal purpose. The court rejected that defence. It emphasized that the governing documents and documentary record consistently recognized Amaranthus, not Mr. Vita, as the account holder and borrower. The Account Information Form identified Amaranthus as the customer. The Account Agreement provided that Amaranthus pledged the CC shares as collateral. All account statements listed Amaranthus as the holder, and the Guarantee on its face guaranteed Amaranthus’s obligations. Mr. Vita himself acknowledged that Amaranthus owned the CC shares deposited when the account was opened. All trading and payment instructions came from Amaranthus’s authorized representatives, not from Mr. Vita. While internal communications sometimes colloquially referred to the account as Mr. Vita’s and Canaccord was plainly aware that loan proceeds were intended to benefit him, these facts did not displace the formal legal structure that Canaccord contracted with Amaranthus and took security from that company. In the judge’s view, Mr. Vita’s illegality argument and the expert’s opinion rested on factual assumptions—that Canaccord had in substance opened a margin account “for Vita,” that he was the control person and true beneficiary of the account, and that he had pledged his own shares—at odds with the documentary and contractual reality. Because those assumptions were not borne out on the evidence, the expert’s analysis of U.S. law did not show that the actual contracts between Canaccord, Amaranthus, and Mr. Vita were formed for an illegal purpose or required illegal performance. The court also held that the summary-trial record was adequate to resolve the illegality issue: the key facts were found in documents and undisputed testimony, and no significant credibility conflicts required a full conventional trial. As a result, the ex turpi causa defence failed, and there was no public-policy bar to enforcing the Guarantee.

Summary trial suitability and overall result
In assessing whether to grant judgment on a summary basis, the court applied the usual factors: amount involved, complexity, potential prejudice, cost and delay of a full trial, and whether credibility was central. Although complex questions of limitation law and illegality were raised, the judge concluded that the necessary factual findings could be made from the documentary record, that credibility was not a decisive issue, and that there was no risk of unfairness or “litigating in slices.” Given the high quantum at stake but clear contractual framework, summary trial was a suitable and efficient vehicle. In the end, the court granted judgment in favour of Canaccord Genuity Corp. under the personal Guarantee. It held that Canaccord is entitled to recover from Mr. Vita: the amounts loaned to Amaranthus under the Account Agreement, all contractual interest properly accruing under the Guarantee, and all reasonable legal fees and expenses on a solicitor-and-own-client basis incurred in enforcing the Guarantee, with all repayments and realizations on the account to be credited. The evidence placed the outstanding debt at approximately US$7.39 million as of July 31, 2025, before final crediting of later payments and any adjustments, but the exact amount of principal, interest, and solicitor-client costs was not fixed in the reasons. Instead, the judge directed that, if the parties could not agree, the full accounting and the assessment of interest and costs be determined and certified by the Registrar. Accordingly, Canaccord is the successful party and obtains judgment for the remaining margin debt, contractual interest, and its enforcement costs, but the precise total monetary sum in its favour cannot be determined from the judgment alone and will depend on the Registrar’s subsequent assessment.